Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content

Table 3 Cox regression analysis for the association of Statins use and risk of incident diabetes in total and sensitivity analysis by excluding those with pre-diabetes at baseline (no Statins use as the reference, HR, 95%CI, P)

From: The use of statins are associated with an increased risk of new-onset diabetes in patients with hypertension and obstructive sleep apnoea, a longitudinal study

 

Crude model

Model 1

Model 2

Model 3

Total participants

    

Intermittent use vs. no use

1.05 (0.85,1.30), 0.663

0.95 (0.77,1.18), 0.666

0.85 (0.79,1.22), 0.851

0.99 (0.79,1.24), 0.946

Persistent use vs. no use

1.84 (1.42,2.39), < 0.001

1.63 (1.26,2.12), < 0.001

1.73 (1.33,2.29), < 0.001

1.77 (1.34,2.34), < 0.001

Sensitivity analysis by excluding those with pre-diabetes at baseline.

Intermittent use vs. no use

0.92 (0.73,1.16), 0.455

0.85 (0.67,1.08), 0.176

0.84 (0.66,1.07), 0.155

086 (0.67.1.10). 0.229

Persistent use vs. no use

1.63 (1.22,2.18), 0.001

1.49 (1.11,1.99), 0.007

1.53 (1.13,2.07), 0.006

1.58 (1.16,2.17), 0.004

  1. Model 1: adjusted for fasting blood glucose; model 2: adjusted for HTN duration + Abdominal circumference + Alanine aminotransferase + Uric acid + Systolic blood pressure + Triglyceride + High density lipoprotein-C + model 1; model 3: adjusted for age + gender + anti-HTN agents + model 2